XASXARX
Market cap146mUSD
Dec 20, Last price
0.68AUD
1D
-2.16%
1Q
38.78%
IPO
-53.74%
Name
Aroa Biosurgery Ltd
Chart & Performance
Profile
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Valuation
Title NZD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
Income | |||||||
Revenues | 63,357 6.83% | 59,309 60.81% | 36,881 79.81% | ||||
Cost of revenue | 75,359 | 63,844 | 45,022 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (12,001) | (4,535) | (8,141) | ||||
NOPBT Margin | |||||||
Operating Taxes | 184 | 11 | 116 | ||||
Tax Rate | |||||||
NOPAT | (12,186) | (4,546) | (8,257) | ||||
Net income | (9,748) | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 180 | 46,774 | |||||
BB yield | |||||||
Debt | |||||||
Debt current | 921 | 523 | 547 | ||||
Long-term debt | 12,720 | 12,782 | 10,375 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 160 | 160 | 152 | ||||
Net debt | (14,088) | (29,692) | (42,431) | ||||
Cash flow | |||||||
Cash from operating activities | (6,765) | (10,861) | |||||
CAPEX | (3,231) | ||||||
Cash from investing activities | 9,309 | 6,791 | |||||
Cash from financing activities | (958) | 34,978 | |||||
FCF | (25,629) | (9,797) | (19,674) | ||||
Balance | |||||||
Cash | 27,727 | 42,997 | 53,354 | ||||
Long term investments | 2 | ||||||
Excess cash | 24,561 | 40,032 | 51,510 | ||||
Stockholders' equity | 87,104 | 143,607 | 140,923 | ||||
Invested Capital | 69,510 | 62,158 | 47,458 | ||||
ROIC | |||||||
ROCE | |||||||
EV | |||||||
Common stock shares outstanding | 343,825 | 342,917 | 342,162 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (12,001) | (1,031) | (5,187) | ||||
EV/EBITDA | |||||||
Interest | 1,163 | 697 | |||||
Interest/NOPBT |